Thorsten Oliver G.
- Country
- Germany
- Department
- Upper-GastroIntestinal-tract
Research Overview
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
- Phase 3 Randomized Study of Adagrasib and Cetuximab Versus Chemotherapy in Advanced Colorectal Cancer with KRAS G12C Mutation Post-First-Line Therapy
- Evaluation of Afatinib Followed by Osimertinib Versus Osimertinib Monotherapy in EGFR-Mutated/T790M-Negative Non-Squamous NSCLC: A Phase IV Randomized Study
Data & Insights
Has run more than one trial at 133 of 324 partner sites.
Specializations
Upper Gastrointestinal Oncology
Investigator concentrates on malignancies of the esophagus, stomach and gastro‑esophageal junction, emphasizing adenocarcinoma subtypes and HER2‑targeted strategies.
- Advanced gastroesophageal adenocarcinoma
- HER2‑positive gastric cancer
- Neoadjuvant chemotherapy for esophageal squamous cell carcinoma
- Claudin‑18.2 expressing tumors
- Peri‑operative immunotherapy
Clinical activity evaluated across multiple German oncology centers.
Hepatobiliary and Pancreatic Malignancies
Research includes primary liver cancer, intra‑ and extra‑hepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma, with focus on targeted and immuno‑oncology approaches.
- hepatocellular carcinoma
- intrahepatic cholangiocarcinoma with FGFR2 fusions
- IDH1‑mutated cholangiocarcinoma
- pancreatic ductal adenocarcinoma with KRAS alterations
- Combination of checkpoint inhibition with anti‑angiogenic agents
Trials coordinated through Frankfurt‑based institutions and affiliated hospitals.
Thoracic Oncology
Engagement in both non‑small cell lung cancer and small‑cell lung cancer, covering ALK‑positive, EGFR‑mutated and PD‑L1‑selected disease subsets.
- ALK‑positive non‑small cell lung cancer
- EGFR‑mutated NSCLC
- PD‑L1 high non‑small cell lung cancer
- Extensive‑stage small‑cell lung cancer
- Combination of immunotherapy with thoracic radiotherapy
Multi‑site participation includes oncology units in Frankfurt and nearby regions.
Colorectal and Anal Cancer
Focus on colon and rectal adenocarcinoma, including molecularly defined subgroups such as KRAS/NRAS wild‑type, BRAF‑mutated and microsatellite instability‑high disease.
- metastatic colorectal cancer with RAS wild‑type
- BRAF‑mutated colorectal carcinoma
- Adjuvant therapy guided by ctDNA in stage II colon cancer
- MSI‑high rectal cancer
- Left‑sided colon cancer treated with anti‑EGFR agents
Research integrates biomarker‑driven trial designs across participating sites.
Rare and Molecularly Targeted Tumors
Investigates less common malignancies and tumors defined by actionable genomic alterations, such as SMARCA4‑deficient neoplasms and FGFR‑altered cholangiocarcinoma.
- SMARCA4‑deficient tumors
- FGFR‑altered cholangiocarcinoma
- Biliary tract cancers with HER2 amplification
- Urothelial carcinoma with PD‑L1 expression
- Solid tumors harboring BRAF alterations
Collaboration with Institut für Klinische Krebsforschung supports translational oncology initiatives.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.